We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

14 hedge funds and large institutions have $14.5M invested in Akari Therapeutics in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

27% more funds holding

Funds holding: 11 → 14 (+3)

0% less ownership

Funds ownership: 0% → 0% (-0%)

61% less capital invested

Capital invested by funds: $37M → $14.5M (-$22.5M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
1
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$2.12M
2
HP
Hikari Power
Japan
+$593K
3
VMI
VHCP Management II
New York
+$561K
4
VKH
Virtu KCG Holdings
New York
+$127K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$71.2K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$3.28M
2
BC
Boxer Capital
California
-$1.05M
3
QF
QVT Financial
New York
-$759K
4
GTC
Ghost Tree Capital
New York
-$516K
5
Deutsche Bank
Deutsche Bank
Germany
-$214K
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$3.77M -$3.28M -415 -29%
VC
2
Vivo Capital
California
$2.43M – – –
BBA
3
Baker Bros. Advisors
New York
$2.29M – – –
NMC
4
NEA Management Company
Maryland
$2.08M – – –
VMI
5
VHCP Management II
New York
$1.97M +$561K +71 +15%
Millennium Management
6
Millennium Management
New York
$987K +$2.12M +268 New
QF
7
QVT Financial
New York
$531K -$759K -96 -37%
HP
8
Hikari Power
Japan
$277K +$593K +75 New
VKH
9
Virtu KCG Holdings
New York
$57K +$127K +16 New
Bank of Montreal
10
Bank of Montreal
Ontario, Canada
$32K +$71.2K +9 New
AG
11
Advisor Group
Arizona
$29K +$63.3K +8 New
UBS Group
12
UBS Group
Switzerland
$13K -$23.7K -3 -50%
JP Morgan Chase
13
JP Morgan Chase
New York
$11K +$23.7K +3 New
Deutsche Bank
14
Deutsche Bank
Germany
$6K -$214K -27 -93%
Morgan Stanley
15
Morgan Stanley
New York
$1K – – –
BC
16
Boxer Capital
California
– -$1.05M -119 Closed
GTC
17
Ghost Tree Capital
New York
– -$516K -58 Closed
Wells Fargo
18
Wells Fargo
California
– -$7K -1 Closed

AKTX Hedge Fund Activity: Q2 2017 in Review

14 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2017, worth a combined $14.5M — down 61% from $37M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AKTX positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 4 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $2.12M. The largest seller was Deerfield Management, cutting an estimated $3.28M.

  • 14 institutional investors held Akari Therapeutics (AKTX) as of Q2 2017, up from 11 in Q1 2017.
  • Funds reported $14.5M of Akari Therapeutics stock for Q2 2017, down 61% quarter-over-quarter.
  • 6 funds opened new Akari Therapeutics positions in Q2 2017 and 3 closed out, a net change of +3 holders.
  • The largest Akari Therapeutics buyer in Q2 2017 was Millennium Management, an estimated $2.12M added.
  • The largest Akari Therapeutics seller in Q2 2017 was Deerfield Management, an estimated $3.28M sold.

Based on aggregated 13F filings for Q2 2017.